These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32627129)

  • 21. A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).
    Cash T; Fox E; Liu X; Minard CG; Reid JM; Scheck AC; Weigel BJ; Wetmore C
    Pediatr Blood Cancer; 2021 Sep; 68(9):e29065. PubMed ID: 33881209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
    Soussain C; Choquet S; Blonski M; Leclercq D; Houillier C; Rezai K; Bijou F; Houot R; Boyle E; Gressin R; Nicolas-Virelizier E; Barrie M; Moluçon-Chabrot C; Lelez ML; Clavert A; Coisy S; Leruez S; Touitou V; Cassoux N; Daniau M; Ertault de la Bretonnière M; El Yamani A; Ghesquières H; Hoang-Xuan K
    Eur J Cancer; 2019 Aug; 117():121-130. PubMed ID: 31279304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extent of re-excision, sequence/timing of salvage re-irradiation, and disease-free interval impact upon clinical outcomes in recurrent/progressive ependymoma.
    Gupta T; Maitre M; Gupta P; Krishnatry R; Chatterjee A; Moiyadi A; Shetty P; Singh V; Chinnaswamy G; Epari S; Sahay A; Patil V; GodaSastri J
    J Neurooncol; 2020 Apr; 147(2):405-415. PubMed ID: 32072441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies.
    Armand P; Lesokhin A; Borrello I; Timmerman J; Gutierrez M; Zhu L; Popa McKiver M; Ansell SM
    Leukemia; 2021 Mar; 35(3):777-786. PubMed ID: 32601377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
    Fouladi M; Stewart CF; Blaney SM; Onar-Thomas A; Schaiquevich P; Packer RJ; Goldman S; Geyer JR; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ
    J Neurooncol; 2013 Sep; 114(2):173-9. PubMed ID: 23836190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune checkpoint inhibitor therapy for recurrent meningiomas: a retrospective chart review.
    Nidamanuri P; Drappatz J
    J Neurooncol; 2022 Apr; 157(2):271-276. PubMed ID: 35301639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
    Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G;
    Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours.
    Federico SM; Caldwell KJ; McCarville MB; Daryani VM; Stewart CF; Mao S; Wu J; Davidoff AM; Santana VM; Furman WL; Pappo AS; Navid F
    Eur J Cancer; 2020 Jun; 132():35-42. PubMed ID: 32325418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas.
    Dilly-Feldis M; Aladjidi N; Refait JK; Parrens M; Ducassou S; Rullier A
    Pediatr Blood Cancer; 2019 May; 66(5):e27571. PubMed ID: 30637917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN).
    DeWire M; Fouladi M; Turner DC; Wetmore C; Hawkins C; Jacobs C; Yuan Y; Liu D; Goldman S; Fisher P; Rytting M; Bouffet E; Khakoo Y; Hwang EI; Foreman N; Stewart CF; Gilbert MR; Gilbertson R; Gajjar A
    J Neurooncol; 2015 May; 123(1):85-91. PubMed ID: 25859842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
    Davis KL; Fox E; Merchant MS; Reid JM; Kudgus RA; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
    Lancet Oncol; 2020 Apr; 21(4):541-550. PubMed ID: 32192573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiotherapy for pediatric central nervous system tumors: a regional cancer centre experience.
    Bauman G; Fisher B; Cairney E; Ranger A; Dar AR; Ross J; Stitt L; MacDonald D
    J Neurooncol; 2004 Jul; 68(3):285-94. PubMed ID: 15332333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trametinib-based Treatment of Pediatric CNS Tumors: A Single Institutional Experience.
    Paul MR; Pehlivan KC; Milburn M; Yeh-Nayre L; Elster J; Crawford JR
    J Pediatr Hematol Oncol; 2020 Nov; 42(8):e730-e737. PubMed ID: 32398601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma.
    Choi Y; Diefenbach CS
    Curr Oncol Rep; 2020 Jan; 22(1):6. PubMed ID: 31981025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH).
    Benesch M; Wagner S; Berthold F; Wolff JE
    J Neurooncol; 2005 Apr; 72(2):179-83. PubMed ID: 15925999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
    Becher OJ; Gilheeney SW; Khakoo Y; Lyden DC; Haque S; De Braganca KC; Kolesar JM; Huse JT; Modak S; Wexler LH; Kramer K; Spasojevic I; Dunkel IJ
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218.
    Deyell RJ; Wu B; Rassekh SR; Tu D; Samson Y; Fleming A; Bouffet E; Sun X; Powers J; Seymour L; Baruchel S; Morgenstern DA
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27540. PubMed ID: 30393943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system.
    Gilheeney SW; Khakoo Y; Souweidane M; Wolden S; Boulad F; Dunkel IJ
    Pediatr Blood Cancer; 2010 Apr; 54(4):591-5. PubMed ID: 19998470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
    Chuk MK; Widemann BC; Minard CG; Liu X; Kim A; Bernhardt MB; Kudgus RA; Reid JM; Voss SD; Blaney S; Fox E; Weigel BJ
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27077. PubMed ID: 29693796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.